We are live on ! Find out more
NNVC icon

NanoViricides

29 hedge funds and large institutions have $1.86M invested in NanoViricides in 2020 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 8 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,525% more call options, than puts

Call options by funds: $65K | Put options by funds: $4K

1.26% less ownership

Funds ownership: 7.35%6.09% (-1.3%)

19% less funds holding

Funds holding: 3629 (-7)

38% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 8

38% less capital invested

Capital invested by funds: $3.01M → $1.86M (-$1.14M)

54% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 13

Holders
29
Holders Change
-7
Holders Change %
-19.44%
% of All Funds
0.51%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
6
Increased
5
Reduced
8
Closed
13
Calls
$65K
Puts
$4K
Net Calls
+$61K
Net Calls Change
-$114K

NNVC Hedge Fund Activity: Q4 2020 in Review

29 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in NanoViricides (NNVC) for Q4 2020, worth a combined $1.86M — down 38% from $3.01M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of NNVC and 6 opened new positions — a net loss of 7 holders — while 8 trimmed existing stakes and 5 added.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $275K. The largest seller was Goldman Sachs, exiting entirely with an estimated $282K sold.

  • 29 institutional investors held NanoViricides (NNVC) as of Q4 2020, down from 36 in Q3 2020.
  • Funds reported $1.86M of NanoViricides stock for Q4 2020, down 38% quarter-over-quarter.
  • 6 funds opened new NanoViricides positions in Q4 2020 and 13 closed out, a net change of -7 holders.
  • The largest NanoViricides buyer in Q4 2020 was Renaissance Technologies, an estimated $275K added.
  • The largest NanoViricides seller in Q4 2020 was Goldman Sachs, an estimated $282K sold.

Based on aggregated 13F filings for Q4 2020.